BACKGROUND: Salivary gland cancers (SGCs) are uncommon and account for less than 5% of all head and neck cancers, but they are histologically heterogeneous. No specific therapy, including targeted agents, has consistently improved clinical outcomes in recurrent/metastatic SGC. Recent studies suggest that vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) play important roles in SGC. Nintedanib is a potent small-molecule, triple-receptor tyrosine kinase inhibitor (VEGFR1, VEGFR2, and VEGFR3; fibroblast growth factor receptor 1 [FGFR1], FGFR2, and FGFR3; and PDGFRa and PDGFRß). This study sought to determine the antitumor activity of nintedanib in patients with recurrent or metastatic SGC. METHODS: This openlabel, multicenter, phase 2, single-arm study was conducted at 11 hospitals in South Korea. Patients with pathologically confirmed recurrent and/or metastatic SGC for whom at least 1 line of systemic chemotherapy had failed were enrolled. Nintedanib was given orally at 200 mg twice a day until disease progression or unacceptable toxicity. The primary endpoint was the response rate. The secondary endpoints were progression-free survival, overall survival, toxicity, and the disease-control rate. The Simon 2-stage minimax design was used. RESULTS: The median age of the patients was 54 years, 60% were female, and 95% had an Eastern Cooperative Oncology Group performance status of 0 or 1. The majority of the patients had adenoid cystic carcinoma (65%), and 40% received at least 2 prior rounds of chemotherapy. After 20 patients were enrolled, the study was stopped because no responders were observed at stage I. There were no partial responses, but the disease-control rate was 75% (15 of 20). The median duration of stable disease was 8.2 months (range, 1.76-12.36 months). At the time of the data cutoff, with a median follow-up of 9.5 months, the median overall survival had not been reached, and the progression-free survival rate at 6 months was 60% (95% confidence interval, 0.34-0.79). Grade 3 adverse events included liver enzyme elevation (25%) and nausea/vomiting (5%). Four patients who required a dose reduction because of a grade 3 liver enzyme elevation showed no further grade 3 events. CONCLUSIONS: Single-agent nintedanib did not yield a partial response but did achieve a 75% disease-control rate with long-term stabilization in SGC patients. Because of the high rate and long duration of disease control with a good safety profile, further investigation is warranted.
INTRODUCTION
Salivary gland cancers (SGCs) are uncommon and account for less than 5% of all cancers of the head and neck.
1,2 They have been classified into 24 well-defined diagnostic entities by the World Health Organization classification on the basis of their cellular, organizational, and architectural composition 3 ; the most common type is mucoepidermoid carcinoma, which is followed by adenoid cystic carcinoma and adenocarcinoma. 4 SGCs vary considerably in their histological patterns and clinical behavior, 1 which includes slow growth and a prolonged clinical course, often with delayed development of distant metastasis in some subtypes. 5, 6 However, other patients suffer rapid progression and die of this cancer; this highlights the need for effective chemotherapy. There is considerable uncertainty about the systemic management of recurrent or metastatic disease. 7 The limited effectiveness of cytotoxic chemotherapy has encouraged research into the molecular biology of the disease and the development of targeted therapies. 8 However, several recent clinical trials using targeted therapeutic agents based on underlying molecular alterations, such as trastuzumab, 9 gefitinib, 10 imatinib, 11, 12 dasatinib, 13 lapatinib, 14 and cetuximab, 15 have not shown promising results. Recently, sorafenib, which targets vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR), demonstrated an 11% response rate in patients with recurrent/metastatic salivary adenoid cystic carcinoma, and this suggests that VEGFR and PDGFR play important roles in this cancer. 16 In addition, treatment with axitinib, which is a potent inhibitor of VEGFR and c-kit, produced partial responses (3 of 33 or 9.1%) and stable disease (SD; 25 of 33 or 75.8%); 11 of 33 patients (33.3%) had SD for 6 months. 17 Nintedanib (formerly BIBF 1120; Boehringer Ingelheim, Ingelheim, Germany) is a potent oral angiokinase inhibitor that targets the proangiogenic pathways mediated by VEGFR1, VEGFR2, VEGFR3, fibroblast growth factor receptor 1 (FGFR1), FGFR2, FGFR3, PDGFRa, and PDGFRb. 18 VEGFR2 is considered to be the crucial receptor involved in the initiation of the formation and maintenance of tumor vasculature. In vitro, the target receptors are all inhibited by nintedanib at low nanomolar concentrations. In in vivo nude mouse models, nintedanib showed good antitumor efficacy at doses of 50 to 100 mg/kg, and it led to a substantial delay in tumor growth or even complete tumor stasis in xenografts of a broad range of human solid tumors. With this background, we conducted a phase 2 study of nintedanib in patients with recurrent or metastatic SGC of the head and neck to evaluate its efficacy and safety.
MATERIALS AND METHODS
This was an open-label, multicenter, single-arm phase 2 trial (NCT02558387 at ClinicalTrials.gov) conducted at 11 hospitals in South Korea. The protocol was reviewed and approved by the institutional review board at each hospital, and the trial was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all patients before participation.
Patient Selection
Patients with locally advanced recurrent or metastatic SGC arising in the head and neck area (mucoepidermoid cancer, adenoid cystic carcinoma, or adenocarcinoma/salivary duct cancer according to the World Health Organization classification) for whom at least 1 line of palliative chemotherapy had failed and who had progressive disease at enrollment were eligible. Patients were required to have at least 1 measurable lesion as defined by the Response Evaluation Criteria in Solid Tumors (version 1.1), an Eastern Cooperative Oncology Group performance status of 0 to 2, adequate bone marrow reserve (neutrophil level > 1500/mm 3 , thrombocyte level > 100,000/mm 3 , hemoglobin level > 9.0 g/dL), and normal renal (creatinine clearance > 45 mL/min) and hepatic function (alanine aminotransferase [ALT]/aspartate aminotransferase [AST] level < 5 3 upper limit of normal, total bilirubin level < 1.5 3 upper limit of normal).
Patients who had a history of VEGFR inhibitor treatment, a history of thrombotic or embolic events within the past 6 months, uncontrolled symptomatic brain metastasis, a severe comorbid illness, or an active infection and women who were pregnant or lactating were excluded from the study.
Treatment Plan and Assessments
Nintedanib was given orally at a dose of 200 mg twice daily on a continuous schedule until disease progression, unacceptable toxicity, or patient withdrawal. Patients could continue treatment beyond progression according to the physician's discretion. One cycle comprised 28 days, and the tumor response was assessed every 2 cycles. The response was evaluated according to the Response Evaluation Criteria in Solid Tumors (version 1.1), and toxicity grading was based on the National Cancer Institute's Common Terminology Criteria for Adverse Events (version 4.03). The dose was reduced to 150 mg twice daily and subsequently to 100 mg twice daily in cases of intolerable toxicity.
Statistical Considerations
The primary endpoint was the objective tumor response rate (including complete and partial overall responses). The secondary endpoints included progression-free survival, overall survival, toxicity, and the disease-control rate. Simon's 2-stage minimax design was applied. A sample size of 36 patients was required to accept the hypothesis that the true response rate was greater than 15% with 80% power and to reject the hypothesis that the response rate was less than 5% with 10.1% significance. In the first state, if there was no response in the initial 20 patients, early termination of the study was required.
Overall survival was defined as the time from registration to death from any cause or to the point of last contact. Progression-free survival was defined as the time from registration to documented progression or death without progression. Survival was assessed on the basis of the last disease assessment in patients without documented progression or death. Survival data were analyzed with the Kaplan-Meier method.
RESULTS

Patient Characteristics and Treatment
Between November 2014 and November 2015, a total of 20 patients were enrolled in this study. After 20 patients were enrolled, the study was stopped because no responses were observed during stage I.
The median age of the participants was 54 years (range, 39-72 years), and the majority of the patients (n 5 19 [95%]) had an Eastern Cooperative Oncology Group performance status of 0 or 1. The most common histological type was adenoid cystic carcinoma (n 5 13 [65%]), which was followed by adenocarcinoma (n 5 3 [15%]) and mucoepidermoid carcinoma (n 5 2 [10%]). Half of the patients had primary metastatic disease, and the other half had recurrent disease after a prior surgery. All patients had a history of palliative chemotherapy, and 40% had received 2 or more cycles of chemotherapy. All patients had distant metastases; sites included the lungs (n 5 20 [100%]), nonregional lymph nodes (n 5 9 [45%]), liver (n 5 6 [30%]), pleura (n 5 3 [15%]), and bone (n 5 2 [10%]). Baseline characteristics are listed in Table 1 .
Efficacy Analysis
A total of 111 cycles of nintedanib were delivered (median, 6 cycles; range, 2-10 cycles). Four patients are currently still in the trial, and 16 patients discontinued the study medication. The main reasons for discontinuation included disease progression (n 5 10 [50%]) and patient refusal (n 5 6 [30%]; Table 2 ). Five patients did not feel that there was an improvement in their disease status, and 1 patient wanted to stop because of grade 2 anorexia. Among the 20 patients enrolled, 19 were evaluable for their tumor response. A radiologic response was not evaluable in 1 patient because of early discontinuation of nintedanib. There were no partial responses, but the diseasecontrol rate was 75% (15 of 20) . The median duration of SD was 8.2 months (range, 1.76-12.36 months). Figure 1 shows the duration of treatment for all patients. Among the 20 patients treated in the study, 18 were alive at the time of the analysis (November 30, 2015) . At the time of the data cutoff, with a median follow-up of 9.5 months, the median overall survival had not been reached, and the progression-free survival rate at 6 months was 60% (95% confidence interval, 38.5%-81.5%; Fig. 2) . The clinical outcome of each patient is described in detail in Supporting Tables 1 and 2 (see online supporting information). 
Safety Analysis
All patients were monitored for adverse events, and all experienced more than 1 adverse event during nintedanib treatment. The most common adverse events of any grade included liver enzyme elevation (30%), diarrhea (35%), and nausea (25%). No hypertension greater than grade 2 (Common Terminology Criteria for Adverse Events), hematologic toxic effects, or significant skin toxicities were observed. Grade 3 adverse events were mainly nausea (5%) and increased AST/ALT levels (25%). One patient experienced a grade 3 c-glutamyl transpeptidase elevation (Table 3) . Four patients (20%) who experienced grade 3 AST/ALT elevations required a dose reduction to 150 mg twice daily, after which no further grade 3 events were observed. There were no treatment-related deaths.
DISCUSSION
Locally advanced recurrent and/or metastatic SGC is incurable even though the disease shows a variable natural history and is often characterized by slow progression. 19 Cytotoxic chemotherapy has a very limited role with relatively poor objective or sustained responses. 7, 19 As a result of recent advances in our understanding of SGC biology and technologies, many interesting genomic alterations have been identified. These include c-kit expression (80%-90% in adenoid cystic carcinoma), 20 epidermal growth factor receptor expression (20%-50%), 20, 21 human epidermal growth factor receptor 2 amplification (20%-35%), [22] [23] [24] androgen receptor expression (67%-92% in salivary duct carcinoma), 25, 26 PIK3-AKT pathway activation, and genomic rearrangements. 8, 27 Consequently, a number of trials using molecularly targeted agents have been performed. However, to date, agents targeting genomic alterations have shown disappointing results.
We report here the results of a phase 2 trial of nintedanib, an oral multikinase inhibitor, in the treatment of advanced SGC. Although the primary response rate objective was not fulfilled, nintedanib showed promising clinical efficacy and achieved a 75% disease-control rate. It can be argued that because of the indolent nature of disease progression in SGC, a 75% disease-control rate might be misleading. However, when we consider that all of the patients experienced failure with previous systemic chemotherapy and progression before treatment, the 8.2-month duration of SD and the 60% rate of progression-free survival at 6 months are quite encouraging. It is notable that 4 of the 20 patients had been under treatment for more than 8 months; this suggests promising clinical efficacy. The relative efficacy of nintedanib observed in this study is considerable in comparison with the efficacy of other targeted molecular agents reported in previous clinical trials. In 2 phase 2 studies investigating the efficacy of imatinib in patients with adenoid cystic carcinoma, there was no objective response. In one study, 11 SD was observed in 60% of the patients (9 of 15), but the median progression-free survival duration was only 10 weeks. Another study reported only 2 patients with SD among 10 adenoid cystic carcinoma patients. 12 In a phase 2 study of lapatinib, SD was observed in 15 of 19 patients, but the median progression-free survival duration was only 3.5 months. Epidermal growth factor receptor inhibition by cetuximab resulted in SD in 20 of 23 patients with a median SD duration of 6 months. 15 In contrast, a phase 2 study of sunitinib achieved prolonged tumor stabilization of more than 6 months in 62% of patients with documented prior progression. 28 In another study examining vorinostat, which is a small-molecule inhibitor of histone deacetylase, 1 of 30 patients exhibited a partial response, and 25 of 30 patients had SD as their best response. 29 Recently, sorafenib and dovitinib, which target multiple receptor tyrosine kinases, also showed a median progression-free survival longer than 6 months. 16, 30 Because of the long duration of SD and the high rate of disease control associated with nintedanib in this study, which is in line with recent results for multi-tyrosine kinase inhibitors, antiangiogenic agents might have potential as a treatment option for recurrent or metastatic SGC.
Safety profiles associated with nintedanib in this study identified mainly gastrointestinal toxicities (nausea, vomiting, and diarrhea), and this is consistent with previously reported results for other solid tumors. 31 Nintedanib was well tolerated, and only 4 patients required a dose reduction because of laboratory abnormalities associated Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, g-glutamyl transpeptidase.
Original Article with ALT/AST elevations. In comparison with other antiangiogenic agents, nintedanib showed a very tolerable safety profile. 16, 28, 30 This study had some limitations. Because of the rarity of this disease, patients with SGC were enrolled regardless of their histological subtype, and this gave rise to heterogeneity. Also, the heterogeneous nature of the clinical course of each subtype made it difficult to evaluate the differential effect of nintedanib. Because of the heterogeneity of SGC, including all subtypes of SGC in 1 trial may not be an ideal approach. Moreover, because of the cytostatic nature of antiangiogenic drugs and the indolent nature of this disease, progression-free survival might be a better study endpoint than the overall response rate.
In conclusion, single-agent nintedanib showed tolerable toxicity and a high rate of disease control with a long duration of disease stabilization in patients with recurrent or metastatic SGC. However, these observations should be used only to generate hypotheses for further testing. Because of the heterogeneity and diverse clinical course of SGC, to determine the efficacy of nintedanib, further investigation of specific histological types is warranted.
FUNDING SUPPORT
This study was supported in part by Boehringer Ingelheim.
CONFLICT OF INTEREST DISCLOSURES
Se-Hoon Lee reports grants and personal fees from AstraZeneca and personal fees from Novartis, Pfizer, Bristol-Myers Squibb, Roche, and Merck Sharp & Dohme outside the submitted work. Nintedanib was provided by Boehringer Ingelheim (Germany); the company was not involved in the collection or analysis of data or in the preparation of the manuscript.
